Dexcom (DXCM) Net Income towards Common Stockholders Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Zimmer Biomet Holdings | 16.17 Bn | 15.75 Bn | 1.51 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.70% |
| Dec 31, 2025 | -8.26% |
| Sep 30, 2025 | 31.49% |
| Jun 30, 2025 | 31.17% |
| Mar 31, 2025 | 39.57% |
| Dec 31, 2024 | 10.35% |
| Sep 30, 2024 | 24.06% |
| Jun 30, 2024 | 73.38% |
| Mar 31, 2024 | 49.40% |
| Dec 31, 2023 | 27.93% |
| Sep 30, 2023 | 20.97% |
| Jun 30, 2023 | 30.86% |
| Mar 31, 2023 | 32.01% |
| Dec 31, 2022 | 63.73% |
| Sep 30, 2022 | 120.90% |
| Jun 30, 2022 | 77.36% |
| Mar 31, 2022 | 34.08% |
| Dec 31, 2021 | 6.46% |
| Sep 30, 2021 | 46.04% |
| Jun 30, 2021 | 42.53% |
| Mar 31, 2021 | 37.66% |
| Dec 31, 2020 | 207.34% |
| Sep 30, 2020 | 29.90% |
| Jun 30, 2020 | 70.75% |
| Mar 31, 2020 | 28.79% |
| Dec 31, 2019 | 131.31% |
| Sep 30, 2019 | 60.97% |
| Jun 30, 2019 | -11.84% |
| Mar 31, 2019 | -16.57% |
| Dec 31, 2018 | -133.30% |
| Sep 30, 2018 | 57.74% |
| Jun 30, 2018 | 37.92% |
| Mar 31, 2018 | -16.87% |
| Dec 31, 2017 | -2.03% |
| Sep 30, 2017 | 35.05% |
| Jun 30, 2017 | 17.05% |
| Mar 31, 2017 | -24.22% |
| Dec 31, 2016 | 9.52% |
| Sep 30, 2016 | -7.20% |
| Jun 30, 2016 | -22.35% |
| Mar 31, 2016 | -10.13% |
| Dec 31, 2015 | 16.57% |
| Sep 30, 2015 | -26.57% |
| Jun 30, 2015 | 20.21% |